Virus News and Research

Latest Virus News and Research

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority. These data from the Phase 3b ODIN study were presented today at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco.

18 Feb 2010

Viral infection can suppress immune response to secondary bacterial infection

A new study reveals how infection with the influenza virus impacts the way that the immune system responds to subsequent infections. The research, published by Cell Press in the February 18th issue of the journal Cell Host and Microbe, provides a new understanding of the physiological and pathological consequences of the flu.

18 Feb 2010

Gene study could pave way for novel methods for plagues and other infectious diseases

An international consortium of scientists, including Universitat Aut-noma de Barcelona (UAB) researcher Deodoro Oliveira, have sequenced the genome of three species of parasitoid wasps of the genus Nasonia.

18 Feb 2010

Multiple, independent European blood centers to report on INTERCEPT Blood System for platelets and plasma

Cerus Corporation announced today that investigators from blood centers in Sweden, Belgium, France and Slovenia will present their experience with the INTERCEPT Blood System for platelets and plasma during a leading international transfusion safety meeting, the XIIth International Haemovigilance Seminar taking place in Dubrovnik, Croatia from February 17 to 19.

18 Feb 2010

Neuroimaging study may lead to new therapeutic treatments for stroke and hearing loss

Duke University Medical Center scientists crowded around a laser-powered microscope in a darkened room to peer into the brain of an anesthetized juvenile songbird right after he heard an adult tutors' song for the first time.

18 Feb 2010

Roche completes enrollment in RG7128 Phase 2b PROPEL study

Pharmasset, Inc. announced today the complete enrollment by Roche of the 12 week RG7128 Phase 2b study (PROPEL) of approximately 400 treatment-naive patients with hepatitis C virus (HCV) genotypes 1 and 4. The study remains blinded to Roche and Pharmasset.

17 Feb 2010

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

Talecris Biotherapeutics announced today that it has received approval from Health Canada for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more purified and concentrated version of PROLASTIN® produced using advances in manufacturing technology. A similar approval for PROLASTIN-C was granted by the U.S. Food and Drug Administration on October 17, 2009.

17 Feb 2010

XMRV infection is not linked to chronic fatigue syndrome

Researchers investigating UK samples have found no association between the controversial xenotropic murine leukaemia virus-related virus (XMRV) and chronic fatigue syndrome (CFS).

17 Feb 2010

ITS secures £8.65M Series-A equity funding round extension to fund synthetic flu vaccine study

Immune Targeting Systems (ITS) Limited (“ITS”), one of the leading developers of synthetic vaccines for mutating viruses, today announced it had secured a Series-A equity funding round extension for £8.65m which brings the total Series A financing to £13.15m. The company’s key investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital (France) are all participating. The round will be kept open until mid-2010 for new potential investors to invest.

17 Feb 2010

Iowa State University researchers awarded 30 ARRA grants worth $16.38M

Iowa State University researchers have so far won 30 grants worth a total $16.38 million from federal agencies awarding money from the American Recovery and Reinvestment Act (ARRA).

17 Feb 2010

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides, Inc. (the "Company"), reports that it has signed a research and development agreement with Dr. Eva Harris’s laboratory at the University of California, Berkeley (UC Berkeley).

17 Feb 2010

Biota Holdings reports total revenue of $61.7M for half-year of 2009

Biota Holdings Limited today announced a half year net profit after tax of $33.5 million, (1H F09: $7.2m). Profit before tax was $41.4 million (1H F09: $10.1m) benefiting significantly from an increase in Relenza royalties.

16 Feb 2010

New program launched for HIV-positive men

The nation's largest surrogacy agency announced today that the number of babies born to HIV-positive clients is expected to more than double in 2010 as its program for HIV-positive men using their own sperm to create embryos continues to expand in the U.S. and abroad.

16 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

Study: sdNVP can lead to HIV treatment failure in women receiving drug to prevent infant infection

A new international study reported in PLoS Medicine confirms that a single dose of nevirapine (sdNVP) can lead to HIV treatment failure in women who receive the drug to prevent transmission of the AIDS virus to their infants. However, the increased risk of failure could only be detected in women who began full HIV treatment within about a year after receiving sdNVP.

16 Feb 2010

Simple, inexpensive test to help determine concussion in athletes

A simple test of reaction time may help determine whether athletes have sustained a concussion (also known as mild traumatic brain injury) and when they are ready to play again, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

16 Feb 2010

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Oncogenic retroviruses are a particular family of viruses that can cause some types of cancer. Thierry Heidmann and his colleagues in the CNRS-Institut Gustave Roussy-Université Paris Sud 11 "Rétrovirus endogènes et éléments rétroïdes des eucaryotes supérieurs" Laboratory have studied these viruses. They have identified a "virulence factor" that inhibits the host immune response and allows the virus to spread throughout the body.

16 Feb 2010

Medivir, Meda announce agreement to commercialize Medivir’s cold sore product, Xerese

Medivir and Meda today announced an agreement for the commercialization of Medivir’s cold sore product which will be marketed in North America under the trade name Xerese™.

15 Feb 2010

Virus News and Research

Latest Virus News and Research

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

Viral infection can suppress immune response to secondary bacterial infection

Gene study could pave way for novel methods for plagues and other infectious diseases

Multiple, independent European blood centers to report on INTERCEPT Blood System for platelets and plasma

Neuroimaging study may lead to new therapeutic treatments for stroke and hearing loss

Roche completes enrollment in RG7128 Phase 2b PROPEL study

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

XMRV infection is not linked to chronic fatigue syndrome

ITS secures £8.65M Series-A equity funding round extension to fund synthetic flu vaccine study

Iowa State University researchers awarded 30 ARRA grants worth $16.38M

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

Biota Holdings reports total revenue of $61.7M for half-year of 2009

New program launched for HIV-positive men

Merck announces global sales of $27.4 billion for full-year 2009

Study: sdNVP can lead to HIV treatment failure in women receiving drug to prevent infant infection

Simple, inexpensive test to help determine concussion in athletes

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Medivir, Meda announce agreement to commercialize Medivir’s cold sore product, Xerese

A new way of characterising biomolecules eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in